Table 3

Patients with lab test results reported in study population of 703,484 initiators of statins or ezetimibe using a 6-month covariate assessment period*
Patient characteristics as determined in CAP All patients Patients with at least 1 of any 23 lab tests1) Patients with at least 1 LDL test Patients with at least 1 HDL test Patients with at least 1 HbA1ctest
Tests performed Results available Tests performed
    Results available
Tests performed
    Results available
Tests performed
    Results available
N N % of total N % of total % of done N % N % % of performed N % N % % of performed N % N % % of performed
All patients 703,484 481,133 68 204,143 29 42 421,708 60 178,254 25 42 417,598 59 176,780 25 42 121,764 17 56,653 8 47
Age
18-40 71,396 52,674 74 23,861 33 45 48,565 68 21,313 30 44 48,021 67 21,150 30 44 12,424 17 5,770 8 46
41-64 489,581 363,406 74 150,096 31 41 329,097 67 131,999 27 40 325,945 67 130,912 27 40 92,076 19 40,635 8 44
65+ 142,507 65,053 46 30,186 21 46 44,046 31 24,942 18 57 43,632 31 24,718 17 57 17,264 12 10,248 7 59
Male sex 378,177 256,537 68 107,876 29 42 225,308 60 94,715 25 42 223,007 59 93,962 25 42 66,202 18 30,286 8 46
# of days hospitalized 1 1 1 0 54 0 51 93 0 55 0 51 91 1 91 1 78 86
Hospitalized in 30 days before treatment initiation (y/n) 52,959 29,933 57 8,871 17 30 15,942 30 5,738 11 36 15,929 30 5,691 11 36 6,353 12 2,483 5 39
Hospitalized in 31 to 180 days before treatment initiation (y/n) 39,304 28,823 73 10,569 27 37 18,889 48 7,546 19 40 18,790 48 7,491 19 40 7,852 20 3,405 9 43
Any coronary hospitalization** 43,507 25,909 60 7,468 17 29 13,821 32 4,911 11 36 13,775 32 4,869 11 35 5,545 13 2,100 5 38
# of cardiologist visits 0 0 0 0 0 0 0 0 0
# of other physician visits 3 4 3 3 3 3 3 4 3
Number of different drugs 4 4 4 4 4 4 4 6 5
# of lab tests performed 6 9 7 9 6 9 6 12 8
Vascular conditions:
Hypercholesterolemia 358,649 308,261 86 100,890 28 33 286,144 80 88,027 25 31 282,875 79 87,016 24 31 74,655 21 23,200 6 31
Hypertension 351,542 244,573 70 100,813 29 41 207,406 59 85,722 24 41 205,531 58 84,903 24 41 75,677 22 33,388 9 44
Heart failure 16,008 10,057 63 3,243 20 32 5,082 32 1,917 12 38 5,064 32 1,891 12 37 2,884 18 1,089 7 38
Acute MI 20,797 11,127 54 2,673 13 24 5,074 24 1,709 8 34 5,046 24 1,698 8 34 1,966 9 714 3 36
Old MI 5,166 3,734 72 998 19 27 2,345 45 714 14 30 2,320 45 705 14 30 873 17 293 6 34
Acute coron. syndrome 63,781 40,721 64 12,776 20 31 25,407 40 9,242 14 36 25,206 40 9,155 14 36 9,328 15 3,791 6 41
TIA/stroke 16,747 9,764 58 3,086 18 32 5,731 34 2,098 13 37 5,692 34 2,080 12 37 2,255 13 845 5 37
Carotid revasc3) 888 598 67 193 22 32 370 42 134 15 36 369 42 135 15 37 137 15 50 6 36
PVD 8,032 5,489 68 1,868 23 34 3,241 40 1,300 16 40 3,260 41 1,284 16 39 1,515 19 642 8 42
Coronary revasc2) 22,575 13,317 59 3,581 16 27 7,098 31 2,377 11 33 7,069 31 2,351 10 33 2,610 12 942 4 36
Peripheral revas 987 748 76 261 26 35 388 39 171 17 44 394 40 170 17 43 204 21 90 9 44
Diabetes 111,684 89,344 80 34,137 31 38 74,576 67 28,032 25 38 73,937 66 27,693 25 37 76,413 68 26,959 24 35
Pre-diabetes 9,916 8,941 90 2,559 26 29 7,957 80 2,032 20 26 7,877 79 2,016 20 26 6,258 63 1,569 16 25
Rheumatoid arthritis 4,523 3,676 81 1,520 34 41 2,650 59 935 21 35 2,620 58 926 20 35 839 19 315 7 38
Recorded obesity 20,533 17,354 85 5,295 26 31 15,138 74 4,307 21 28 14,971 73 4,251 21 28 6,897 34 1,956 10 28
COPD 27,318 18,918 69 6,382 23 34 13,236 48 4,855 18 37 13,144 48 4,818 18 37 4,557 17 1,708 6 37
Use of oxygen tank 105 59 56 20 19 34 41 39 13 12 32 42 40 13 12 31 20 19 8 8 40
Plan type: Indemnity 3,942 3,391 86 807 20 24 3,149 80 696 18 22 3,132 79 698 18 22 823 21 181 5 22
HMO 202,910 109,821 54 100,426 49 91 95,306 47 92,427 46 97 94,360 47 91,683 45 97 28,471 14 30,241 15 106
Medicare Advantage 62,459 37,744 60 24,757 40 66 28,014 45 20,468 33 73 27,758 44 20,304 33 73 11,658 19 8,622 14 74
Medicare Supplemental 43,645 15,519 36 1,294 3 8 7,822 18 1,000 2 13 7,745 18 994 2 13 2,647 6 285 1 11
Other 22,274 10,323 46 4,057 18 39 8,677 39 3,486 16 40 8,593 39 3,456 16 40 2,422 11 1,153 5 48
Preferred Provider Org. 368,254 304,335 83 72,802 20 24 278,740 76 60,177 16 22 276,010 75 59,645 16 22 75,743 21 16,171 4 21
State of residence: 1 194,150 97,286 50 51,523 27 53 83,875 43 46,332 24 55 82,694 43 46,342 24 56 25,050 13 16,146 8 64
2 23,642 20,159 85 9,281 39 46 18,674 79 8,517 36 46 18,678 79 8,521 36 46 5,416 23 2,352 10 43
3† 5,006 3,783 76 359 7 9 3,420 68 318 6 9 3,395 68 311 6 9 923 18 85 2 9
4 64,242 53,997 84 30,197 47 56 49,458 77 27,231 42 55 48,892 76 26,855 42 55 13,198 21 7,569 12 57
5 36,365 29,200 80 4,805 13 16 25,522 70 3,635 10 14 25,903 71 3,604 10 14 6,872 19 917 3 13
6 48,045 37,348 78 8,630 18 23 32,056 67 6,583 14 21 31,752 66 6,476 13 20 8,929 19 1,723 4 19
7 13,847 11,833 85 359 3 3 10,773 78 260 2 2 10,647 77 259 2 2 2,678 19 44 0 2
8 28,450 23,108 81 6,178 22 27 20,781 73 5,309 19 26 20,627 73 5,276 19 26 5,877 21 1,461 5 25
9 8,703 7,401 85 1,089 13 15 6,789 78 875 10 13 6,772 78 886 10 13 1,812 21 243 3 13
10† 3,753 2,464 66 1,183 32 48 2,226 59 1,097 29 49 2,188 58 1,083 29 49 710 19 369 10 52
11 4,864 3,610 74 2,310 47 64 3,217 66 2,030 42 63 3,137 64 2,029 42 65 1,015 21 648 13 64
12 64,237 24,644 38 36,009 56 146 15,190 24 32,988 51 217 14,979 23 32,722 51 218 6,068 9 12,646 20 208
13 85,926 71,455 83 22,481 26 31 63,065 73 18,108 21 29 62,703 73 17,993 21 29 19,587 23 5,464 6 28
Other 44,110 35,064 79 5,628 13 16 31,850 72 4,867 11 15 31,462 71 4,839 11 15 8,949 20 1,446 3 16
14† 3,804 3,311 87 116 3 4 3,113 82 100 3 3 3,107 82 99 3 3 876 23 31 1 4
15 74,340 56,470 76 23,995 32 42 51,699 70 20,004 27 39 50,662 68 19,485 26 38 13,804 19 5,509 7 40

* Study period starts July 1, 2005, ensuring a minimum CAP of 6 months with lab test results coverage and a pre-CAP of 6 months.

** Hospitalization with primary discharge code for acute MI, ACS, PCTA, PCI, CABG.

† States with no WellPoint presence.

1) This is limited to 23 lab test results reported in our study database.

2) PCTA, PCI, CABG.

3) Carotid stent, carotid endarterectomy.

Schneeweiss et al.

Schneeweiss et al. BMC Medical Research Methodology 2012 12:180   doi:10.1186/1471-2288-12-180

Open Data